Anavo Therapeutics utilizes its IGNITE platform to develop allosteric modulators targeting phosphatases, a class of enzymes that have been largely overlooked in drug discovery despite their critical role in regulating cellular signaling pathways. By focusing on phosphatase biology, Anavo aims to create first-in-class therapeutics for various diseases, addressing the significant gap in approved drugs that specifically target these enzymes.
Funding
$30.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Phosphatases, a class of enzymes critical in regulating cellular signaling pathways, have been largely overlooked in drug discovery compared to kinases. Despite their importance in various diseases, there is a significant lack of approved drugs specifically designed to target phosphatases.
Solution
Anavo Therapeutics is developing allosteric modulators that target phosphatases, utilizing its IGNITE platform to access this previously undruggable target class. By focusing on phosphatase biology, Anavo aims to create first-in-class therapeutics for a range of diseases. The IGNITE platform combines deep knowledge of phosphatase target families, improved protein structural methods, high-throughput screening, and specificity technologies to modulate phosphatase signaling pathways. Anavo's allosteric approach avoids the enzyme's active sites, allowing for a thorough mechanistic understanding of drug candidates.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for diseases regulated by phosphatase signaling pathways, particularly in oncology.
Features
- IGNITE platform for phosphatase-based drug discovery
- Development of allosteric modulators targeting phosphatases
- Focus on phosphatase-driven disease biology
- Improved protein structural methods for drug design
- High-throughput screening methods for identifying drug candidates
- Specificity and selectivity technologies for targeting phosphatases
- Proprietary portfolio of cancer-targeting therapeutic programs